What we don't know about Avastin might hurt us

被引：36

作者：

Gillies, Mark C. ^{[1
]}

机构：

[1] Univ Sydney, Save Sight & Eye Hlth Inst, Sydney, NSW 2001, Australia

来源：

ARCHIVES OF OPHTHALMOLOGY | 2006年 / 124卷 / 10期

关键词：

D O I：

10.1001/archopht.124.10.1478

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

引用

页码：1478 / 1479

页数：2

共 18 条

[1] Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen [J].

Chen, Y ;

Wiesmann, C ;

Fuh, G ;

Li, B ;

Christinger, HW ;

McKay, P ;

de Vos, AM ;

Lowman, HB .

JOURNAL OF MOLECULAR BIOLOGY, 1999, 293 (04) :865-881

[2] Role of vascular endothelial growth factor in regulation of physiological angiogenesis [J].

Ferrara, N .

AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2001, 280 (06) :C1358-C1366

[3] Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration [J].

Gaudreault, J ;

Fei, D ;

Rusit, J ;

Suboc, P ;

Shiu, V .

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46 (02) :726-733

[4] Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer [J].

Gordon, MS ;

Margolin, K ;

Talpaz, M ;

Sledge, GW ;

Holmgren, E ;

Benjamin, R ;

Stalter, S ;

Shak, S ;

Adelman, DC .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :843-850

[5] Pegaptanib for neovascular age-related macular degeneration [J].

Gragoudas, ES ;

Adamis, AP ;

Cunningham, ET ;

Feinsod, M ;

Guyer, DR .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) :2805-2816

[6] From angiogenesis to neuropathology [J].

Greenberg, DA ;

Jin, KL .

NATURE, 2005, 438 (7070) :954-959

[7] Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo [J].

Jin, KL ;

Zhu, YH ;

Sun, YJ ;

Mao, XO ;

Xie, L ;

Greenberg, DA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (18) :11946-11950

[8] Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration - Twelve-week results of an uncontrolled open-label clinical study [J].

Michels, S ;

Rosenfeld, PJ ;

Puliafito, CA ;

Marcus, EN ;

Venkatraman, AS .

OPHTHALMOLOGY, 2005, 112 (06) :1035-1047

[9] Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following lntravitreal administration [J].

Mordenti, J ;

Cuthbertson, RA ;

Ferrara, N ;

Thomsen, K ;

Berleau, L ;

Licko, V ;

Allen, PC ;

Valverde, CR ;

Meng, YG ;

Fei, DTW ;

Fourre, KM ;

Ryan, AM .

TOXICOLOGIC PATHOLOGY, 1999, 27 (05) :536-544

[10] Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration [J].

Oosthuyse, B ;

Moons, L ;

Storkebaum, E ;

Beck, H ;

Nuyens, D ;

Brusselmans, K ;

Van Dorpe, J ;

Hellings, P ;

Gorselink, M ;

Heymans, S ;

Theilmeier, G ;

Dewerchin, M ;

Laudenbach, V ;

Vermylen, P ;

Raat, H ;

Acker, T ;

Vleminckx, V ;

Van den Bosch, L ;

Cashman, N ;

Fujisawa, H ;

Drost, MR ;

Sciot, R ;

Bruyninckx, F ;

Hicklin, DJ ;

Ince, C ;

Gressens, P ;

Lupu, F ;

Plate, KH ;

Robberecht, W ;

Herbert, JM ;

Collen, D ;

Carmeliet, P .

NATURE GENETICS, 2001, 28 (02) :131-138

← 1 2 →